About Us 关于我们
Miraclebest is a product of Lifetree Health LLC. Lifetree is dedicated to providing an alternative safer way to help with the many cardiovascular diseases such as heart attack and stroke facing the world today. Our flagship product is Miraclebest.
The main component of Miraclebest is Serrapeptase. Miraclebest's serrapeptase has a very high concentration of serrapeptase fibrin per gram due to our technologies for unique recipe. The Serrapeptase enzyme can have great effects on cardiovascular health.
Miraclebest has 60 tablets per bottle, and lasts for 1 month. Miraclebest should be taken on an empty stomach once in the morning and one time before bedtime. The Miraclebest tablets can be swallowed whole, or chewed.
Serrapeptase is an enzyme and has been shown to help with decreasing inflammation and dissolve and clear calcium and plaque buildup in arteries, blood vessels and capillaries, and improving blood circulation throughout the body.
The ingredients have been used safely for over 30 years in Germany and Japan. Serrapeptase has over 40 documented clinical studies. There is some evidence of gastrointestinal irritation in elderly patients with use of the product over a long period of time, though this is rare.
Lifetree Health have been selling Miraclebest for over 12 years (Previously the product was named Miraclezyme). Lifetree contracts the proprietary formula of Miraclebest to a FDA audited, NSF and cGMP certified manufacturing company in Arizona.
Serrapeptase has been safely and widely used in Europe and Asia for more than 30 years. They are helpful in conditions of the pathological hypercoagulation tendencies common among modern people. Serrapeptase has been referred to as the miracle enzyme in European culture, benefiting people with conditions of osteoarthritis, rheumatoid arthritis, and sinusitis, etc., also showing anti-inflammatory properties. Serrapeptase may prove to be an effective pain reliever. Produced in the intestines of silk worms, this enzymes helps the matured adult silk worm-moth, break free from it’s hard cocoon walls.
Use of Serrapeptase resulted in greater benefits in cardiovascular system. Recent studies suggest that these enzymes may significantly reduce the amount of arterial plaques (unwanted protein/fatty deposits/dead cell debris in the arteries), in addition to greatly reducing the chance of developing blood clots which can cause heart attack and stroke.
The Serrapeptase tablets are enteric coated, preventing the precious enzymes from being digested by acidity of the stomach. During the process of passing through the small intestine, the peptides from the enzyme molecules can be absorbed, entering blood stream, and even recovering it’s activity in the blood. They are capable of getting rid of fibrin clots in the blood and non-living protein deposits on the vascular wall.
People with bleeding disorders, such as hemophilia or a group of diseases called “hemorrhagic diathesias,” should not take . People with ongoing bleeding problems, including ulcers, recent surgery, recent major trauma, or hemorrhoids, should not take . Anyone who has ever suffered intracranial bleeding, or who has had neurosurgery or ischemic stroke in the previous six months, should also avoid it. Severe uncontrolled high blood pressure is also a contraindication for its use. Last, those taking blood-thinning drugs such as heparin, Coumadin® or aspirin, should use this product only if advised and carefully monitored by their prescribing physician. Anyone suffering any medical condition that might involve bleeding or coagulation issues should check with a health care professional before using.
The above information is based on the following research publications. All information provide here has not been evaluated by FDA. The serrapeptase is not used to replace drugs for the purposes of diagnosis, prevention and treatments for diseases.
- Heinrich, J. et al. “Fibrinogen and factor VII in the prediction of coronary risk.” Arterioscler Thromb 1994, 14:54-59.
- Hager, K. et al. “Fibrinogen and Aging.” Aging (Milano) 1994, 6:133-38.
- Montalescot, G. et al. “Fibrinogen as a risk factor for coronary heart disease.” Eur Heart J 1998, 19 Suppl H:H11-17.
- Interview with Doctor of Medicine Hiroyuki Sumi, Japan Bio Science Laboratory Co., Ltd., 1998.
- Kee, W. et al. “The treatment of breast engorgement with serrapeptase (Danzen&Mac226;): a randomized double-blind controlled trial.” Singapore Med J 1989, 30:48-54.
- Tomoda, K. and Miyatam, K. “Some information on the composition of tracheal secretions before and after the administration of Danzen&Mac226;” Exper Ther 1972, 477:9-16.
- Mazzone, A. et al. “Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo.” J Int Med Res 1990, 18:379-88.
- Miyata, K. “Intestinal absorption of serratia peptidase.” J Appl Biochem 1980, 2:111-16.
- Moriya, N. et al. “Intestinal absorption of serrapeptase (TSP) in rats.” Biotechnol Appl Biochem 1994, 20(pt.1):101-08.
- Esch, P. et al. “A reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase—a prospective study” (in German). Fortschr Med 1989,107:67-68,71-72.
You can order through this website. Lifetree Health LLC, Miraclebest.com uses SSL secure server. We take credit cards, 银联卡 Unionpay ， and 微信支付Wechat Pay.
Our email: Support@LifetreeUS.com
or by phone: (847) 507-5887